Electronics and Telecommunications Trends (전자통신동향분석)

Electronics and Telecommunications Research Institute (한국전자통신연구원)
권호 표지
DOI QR코드

DOI QR Code

R&D Trends in Bioelectronic Medicines

전자약 연구개발 동향

  • Published : 2020.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Precise detection and modulation of electrical signal patterns passing through peripheral nerves connecting organs and brainstems, referred to as electroceuticals or bioelectronic medicines, have emerged as a new type of treatments for neural disorders and chronic diseases. With the rapid advancements in neural interface technologies, electroceuticals are the focus of treatments for these disorders or diseases. In this paper, we introduced electroceuticals as an extension of neuromodulation for the treatment of chronic diseases, such as diabetes, rheumatoid arthritis, obesity, and bladder dysfunction, without side effects that are unavoidably elicited when conventional drugs are taken. Further, this paper reviewed the anatomy of the peripheral nervous system, treatment examples for chronic diseases, technological demands for peripheral nerve interfacing, global R&D programs and market trends for electroceuticals, and prospects on electroceuticals.

Keywords

Acknowledgement

본 기술동향 기고문은 한국전자통신연구원 연구운영비지원사업의 일환으로 수행되었음[20ZB1165, ICT 창의기술 개발].

References

  1. C. Bouton, "Bioelectronic medicine: molecular mechanisms," SRC/NSF Workshop on Microsyst for Bioelecton Med, IBM Conference Center, Washington, D.C., USA, Apr. 12-13, 2017.
  2. S. Mishra, "Electroceuticals in medicine-The brave new future," Indian Heart J., vol. 69, no. 5, 2017, pp. 685-686. https://doi.org/10.1016/j.ihj.2017.10.001
  3. B. J. Seicol et al., "Neuromodulation of metabolic functions: from pharmaceuticals to bioelectronics to biocircuits," J. Biol. Eng., vol. 13, 2019, Article no. 67.
  4. K. Devarakonda and S. Stanley, "Investigating metabolic regulation using targeted neuromodulation," Ann. New Yorl Academy Sci., vol. 1411, no. 1, 2018, pp. 83-95. https://doi.org/10.1111/nyas.13468
  5. K. Famm, "A-jump start for elelctroceuticals," Nature, vol. 496, no. 11, 2013, pp. 159-161. https://doi.org/10.1038/496159a
  6. R. Carnagarin et al., "Autonomic regulation of glucose homeostasis: a specific role for sympathetic nervous system activation," Curr. Diab. Rep., vol. 18, no. 11, 2018, doi: 10.1007/s11892-018-1069-2.
  7. P. S. Olofsson and K. J. Tracey, "Bioelectronic medicine: technology targeting molecular mechanisms for therapy," J. Intern. Med., vol. 282, no. 1, 2017, doi: 10.1111/joim.12624.
  8. G. de Lartigue, "Role of the vagus nerve in the development and treatment of diet-induced obesity," J. Physiol., vol. 594, no. 20, 2016, doi: 10.1113/JP271538.
  9. H. Divanovic et al., "Effects of electrical stimulation as a new method of treating diabetes on animal models: review," IFMBE Proc., vol. 62, 2017, doi: 10.1007/978-981-10-4166-2_38.
  10. B. Thorens, "Neural regulation of pancreatic islet cell mass and function," Diabetes Obes. Metab., vol. 16, 2014, pp. 87-95. https://doi.org/10.1111/dom.12346
  11. U. S. Food and Drug Administration, "VNS therapy system: FDA," premarket approval (PMA)-Depression (Online) (updated 2005).
  12. J. P. O'Reardon, P. Cristancho and A.D. Peshek, "Vagus nerve stimulation (VNS) and treatment of depression: to the brainstem and beyond," Psychiatry (Edgmont), vol. 3, no. 5, 2006, pp. 54-63.
  13. E. N. Marieb, "Human anatomy," 6th ed., Benjamin Cummings, 2010.
  14. L. K. McCorry, "Physiology of the autonomic nervous system," Am. J. Pharm. Educ., vol. 71, no. 4, 2007, Article no. 78, doi: 10.5688/aj710478.
  15. F. S. Routledge et al., "Improvements in heart rate variability with exercise therapy," Can. J. Cardiol., vol. 26, 2010, pp. 303-312. https://doi.org/10.1016/S0828-282X(10)70395-0
  16. A. Nesvold et al., "Increased heart rate vatiability during nondirective meditation," Eur. J. Prev. Cardiol., vol. 19, 2012, pp. 773-780. https://doi.org/10.1177/1741826711414625
  17. S. Breit et al., "Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders," Front Psychiatry, vol. 9, 2018, Article no. 44, doi:10.3389/fpsyt.2018.00044.
  18. B. Bonaz et al., "Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflamatory pathway," Neurogastroenterol Motil, vol. 25, no. 3, 2013, pp. 208-221. https://doi.org/10.1111/nmo.12076
  19. K. J. Tracey, "The inflamatory reflex," Nature, vol. 420, 2002, pp. 853-859. https://doi.org/10.1038/nature01321
  20. S. C. Payne, J. B. Furness and M. J. Stebbing, "Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms," Nat. Rev. Gastro. Hepat., vol. 16, no. 2, 2019, pp. 89-105. https://doi.org/10.1038/s41575-018-0078-6
  21. U. S. Food and Drug Administration, "VNS therapy system: FDA, premarket approval (PMA)-Epilepsy" (Online) (updated 1997).
  22. J. M. Morton et al., "Effect of vagal nerve blockade on moderate obesity with an obesity-related comorbid condition: the ReCharge Study," Obes. Surg., vol. 26, 2016, pp. 983-989. https://doi.org/10.1007/s11695-016-2143-y
  23. U. S. Food and Drug Administration, "Devices@FDA: Medtronic interstim sacral nerve stimulation therapy system" (Online) (updated 2011).
  24. L. V. Borovikova et al., "Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin," Nature, vol. 405, 2000, pp. 458-461. https://doi.org/10.1038/35013070
  25. F. A. Koopman et al., "Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis," Proc. Natl. Acad. Sci. USA, vol. 113, no. 29, 2016, pp. 8284-8289. https://doi.org/10.1073/pnas.1605635113
  26. World Health Organization, "Global Report on Diabetes," 2016.
  27. S. Trevitt, S. Simpson, and A. Wood, "Artificial pancreas device systems for the closed-loop control of type 1 diabetes: What systems are in development?" J. Diabetes Sci. Technol., vol. 10, no. 3, 2016, pp. 714-723. https://doi.org/10.1177/1932296815617968
  28. A. Haidar et al., "Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled cross over trial," Lancet Diabetes Endocrinol., vol. 3, 2015, pp. 17-26. https://doi.org/10.1016/S2213-8587(14)70226-8
  29. A. Guemes and P. Georgiou, "Review of the role of the nervous system in glucose homeostasis and future perspectives towards the management of diabetes," Bioelectron Med., vol. 4, 2018, doi: 10.1186/s42234-018-0009-4.
  30. C. M. Hales, "Prevalence of obesity among adults and youth: United States 2015-2016," NCHS Data Brief, vol. 288, 2017, pp. 1-8.
  31. E. A, Katsareli and G. V. Dedoussis, "Biomarkers in the Field of obesity and its related comorbidities," Expert Opin. Ther. Targets, vol. 18, 2014. pp. 385-401. https://doi.org/10.1517/14728222.2014.882321
  32. R. Kassir et al., "Effects of vagus nerve stimulation on weight loss and associated disorders: a therapeutic perspective," J. Med. Diagn Meth., vol. 3, 2014, doi: 10.4172/2168-9784.1000e110.
  33. M. L. Ganz et al., "Economic costs of over active bladder in the United States," Urology, vol. 75, 2010, pp. 526-532. https://doi.org/10.1016/j.urology.2009.06.096
  34. J. W. Boggs et al. "Frequency dependent selection of reflexes by pudendal afferents in the cat," J. Physiol., vol. 577, 2006, pp. 115-126. https://doi.org/10.1113/jphysiol.2006.111815
  35. X. Navarro et al., "A critical review of interfaces with the peripheral nervous system for the control of neuroprostheses and hybrid bionic systems," J. Peripher Nerv. Syst., vol. 10, 2005, pp. 229-258. https://doi.org/10.1111/j.1085-9489.2005.10303.x
  36. E. H. Rijnbeek, N. Eleveld, and W. Olthuis, "Update on peripheral nerve electrodes for closed-loop neuroprosthetics," Front Neurosci, vol. 12, 2018, doi: 10.3389/fnins.2018.00350.
  37. C. Russell, D. Roche, and S. Chakrabarty, "Peripheral nerve bionic interface: a review of electrodes," Int. J. Intell. Robot. Appl., vol. 3, 2019, pp. 11-18. https://doi.org/10.1007/s41315-019-00086-3
  38. S. Eldabe, E. Buchser, and R.V. Duarte, "Complications of spinal cord stimulation and peripheral nerve stimulation techniques: a review of the literature," Pain Med, vol. 17, 2016, pp. 325-336.
  39. V. H. Desai et al., "Chronic sensory-motor activity in behaving animals using regenerative multi-electrode interfaces," in Proc. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc., Chicago, IL, USA, Aug. 2014, pp. 1973-1976.
  40. X. A. Maul et al., "Microcurrent technology for rapid relief of sinus pain: a randomized placebo-controlled, double-blinded clinical trial," Int. Forum Allergy Rhinol., vol. 9, 2019, pp. 352-356. https://doi.org/10.1002/alr.22280
  41. K. Birmingham et al., "Bioelectronic medicines: a research roadmap," Nat. Rev. Drug Discov., vol. 13, 2014, pp. 399-400. https://doi.org/10.1038/nrd4351
  42. NIH, https://ncats.nih.gov/sparc
  43. S. F. Cogan et al., "Tissue damage thresholds during therapeutic electrical stimulation," J. Neural Eng., vol. 13, 2016, doi: 10.1088/1741-2560/13/2/021001.
  44. Reports and Data, "Electroceuticals / bioelectric medicine market analysis," 2019.
  45. Markets & Markets, "Electroceuticals / bioelectric medicine market by product (pacemakers, cochlear implants, spinal cord stimulators), type of device (implantable, non-invasive), application (arrhythmia, depression, migraine), end user (hospitals) - Global Forecast to 2021."
  46. Verified Market Research, "Global electroceuticals/ bioelectric medicine market size by type, by product, by application, by geographic scope and forecast," 2019.
  47. Alliance for Advancing Bioelectronic Medicine, "Building a bioelectronic medicine movement 2019: insights from leaders in industry, academia, and research," Bioelectron Med, vol. 6, 2020, 1.
  48. https://www/weforum.org /agenda/2018/09/top-10-emerging-technologies-of-2018.
  49. https://www.idtechex.com/en/research-article/six-firsts-inelectroceutical-approvals-of-2019/17604.